FindTrial
Sign In

Prognostic value of 18F-FDG PET/CT radiomics in patients with B-cell lymphoma treated with CD19/CD22 dual-target CAR-T

Prognostic value of 18F-FDG PET/CT radiomics in patients with B-cell lymphoma treated with CD19/CD22 dual-target CAR-T

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100052247
Enrollment
Unknown
Registered
2021-10-23
Start date
2021-10-26
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell lymphoma

Interventions

Gold Standard:Pathological diagnosis
Index test:18F-FDG PET-CT

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years; 2. Receive CD19/CD22 dual-target CAR-T therapy; 3. 18F-FDG PET/CT imaging was performed before receiving CAR-T therapy.

Exclusion criteria

Exclusion criteria: 1. Previously known history of other malignancies; 2. Incomplete imaging data.

Design outcomes

Primary

MeasureTime frame
Progression-free survival;Overall survival;—

Countries

China

Contacts

Public ContactDeng Shengming

The First Affiliated Hospital of Soochow University

dshming@163.com+86 15051510189

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026